Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.

Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ.

Sci Rep. 2018 Aug 21;8(1):12771. doi: 10.1038/s41598-018-30922-8.

2.

Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.

Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ.

Sci Rep. 2018 Jul 13;8(1):10614. doi: 10.1038/s41598-018-29043-z. Erratum in: Sci Rep. 2018 Aug 21;8(1):12771.

3.

Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells.

Vinci M, Burford A, Molinari V, Kessler K, Popov S, Clarke M, Taylor KR, Pemberton HN, Lord CJ, Gutteridge A, Forshew T, Carvalho D, Marshall LV, Qin EY, Ingram WJ, Moore AS, Ng HK, Trabelsi S, H'mida-Ben Brahim D, Entz-Werle N, Zacharoulis S, Vaidya S, Mandeville HC, Bridges LR, Martin AJ, Al-Sarraj S, Chandler C, Sunol M, Mora J, de Torres C, Cruz O, Carcaboso AM, Monje M, Mackay A, Jones C.

Nat Med. 2018 Aug;24(8):1204-1215. doi: 10.1038/s41591-018-0086-7. Epub 2018 Jul 2.

4.

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.

Pettitt SJ, Krastev DB, Brandsma I, Dréan A, Song F, Aleksandrov R, Harrell MI, Menon M, Brough R, Campbell J, Frankum J, Ranes M, Pemberton HN, Rafiq R, Fenwick K, Swain A, Guettler S, Lee JM, Swisher EM, Stoynov S, Yusa K, Ashworth A, Lord CJ.

Nat Commun. 2018 May 10;9(1):1849. doi: 10.1038/s41467-018-03917-2.

5.

E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.

Bajrami I, Marlow R, van de Ven M, Brough R, Pemberton HN, Frankum J, Song F, Rafiq R, Konde A, Krastev DB, Menon M, Campbell J, Gulati A, Kumar R, Pettitt SJ, Gurden MD, Cardenosa ML, Chong I, Gazinska P, Wallberg F, Sawyer EJ, Martin LA, Dowsett M, Linardopoulos S, Natrajan R, Ryan CJ, Derksen PWB, Jonkers J, Tutt ANJ, Ashworth A, Lord CJ.

Cancer Discov. 2018 Apr;8(4):498-515. doi: 10.1158/2159-8290.CD-17-0603.

6.

ATR Is a Therapeutic Target in Synovial Sarcoma.

Jones SE, Fleuren EDG, Frankum J, Konde A, Williamson CT, Krastev DB, Pemberton HN, Campbell J, Gulati A, Elliott R, Menon M, Selfe JL, Brough R, Pettitt SJ, Niedzwiedz W, van der Graaf WTA, Shipley J, Ashworth A, Lord CJ.

Cancer Res. 2017 Dec 15;77(24):7014-7026. doi: 10.1158/0008-5472.CAN-17-2056. Epub 2017 Oct 16.

7.

Modeling Therapy Resistance in BRCA1/2-Mutant Cancers.

Dréan A, Williamson CT, Brough R, Brandsma I, Menon M, Konde A, Garcia-Murillas I, Pemberton HN, Frankum J, Rafiq R, Badham N, Campbell J, Gulati A, Turner NC, Pettitt SJ, Ashworth A, Lord CJ.

Mol Cancer Ther. 2017 Sep;16(9):2022-2034. doi: 10.1158/1535-7163.MCT-17-0098. Epub 2017 Jun 15.

8.

Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.

Nikkilä J, Kumar R, Campbell J, Brandsma I, Pemberton HN, Wallberg F, Nagy K, Scheer I, Vertessy BG, Serebrenik AA, Monni V, Harris RS, Pettitt SJ, Ashworth A, Lord CJ.

Br J Cancer. 2017 Jun 27;117(1):113-123. doi: 10.1038/bjc.2017.133. Epub 2017 May 23.

9.

Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cells.

Pettitt SJ, Krastev DB, Pemberton HN, Fontebasso Y, Frankum J, Rehman FL, Brough R, Song F, Bajrami I, Rafiq R, Wallberg F, Kozarewa I, Fenwick K, Armisen-Garrido J, Swain A, Gulati A, Campbell J, Ashworth A, Lord CJ.

Sci Data. 2017 Mar 1;4:170020. doi: 10.1038/sdata.2017.20.

10.

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.

Williamson CT, Miller R, Pemberton HN, Jones SE, Campbell J, Konde A, Badham N, Rafiq R, Brough R, Gulati A, Ryan CJ, Francis J, Vermulen PB, Reynolds AR, Reaper PM, Pollard JR, Ashworth A, Lord CJ.

Nat Commun. 2016 Dec 13;7:13837. doi: 10.1038/ncomms13837.

11.

RAD18, WRNIP1 and ATMIN promote ATM signalling in response to replication stress.

Kanu N, Zhang T, Burrell RA, Chakraborty A, Cronshaw J, DaCosta C, Grönroos E, Pemberton HN, Anderton E, Gonzalez L, Sabbioneda S, Ulrich HD, Swanton C, Behrens A.

Oncogene. 2016 Jul 28;35(30):4020. doi: 10.1038/onc.2015.500. Epub 2016 Jun 27. No abstract available.

PMID:
27345393
12.

Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines.

Campbell J, Ryan CJ, Brough R, Bajrami I, Pemberton HN, Chong IY, Costa-Cabral S, Frankum J, Gulati A, Holme H, Miller R, Postel-Vinay S, Rafiq R, Wei W, Williamson CT, Quigley DA, Tym J, Al-Lazikani B, Fenton T, Natrajan R, Strauss SJ, Ashworth A, Lord CJ.

Cell Rep. 2016 Mar 15;14(10):2490-501. doi: 10.1016/j.celrep.2016.02.023. Epub 2016 Mar 3.

13.

RAD18, WRNIP1 and ATMIN promote ATM signalling in response to replication stress.

Kanu N, Zhang T, Burrell RA, Chakraborty A, Cronshaw J, DaCosta C, Grönroos E, Pemberton HN, Anderton E, Gonzalez L, Sabbioneda S, Ulrich HD, Swanton C, Behrens A.

Oncogene. 2016 Jul 28;35(30):4009-19. doi: 10.1038/onc.2015.427. Epub 2015 Nov 9. Erratum in: Oncogene. 2016 Jul 28;35(30):4020.

14.

Breast cancer intratumor genetic heterogeneity: causes and implications.

Ng CK, Pemberton HN, Reis-Filho JS.

Expert Rev Anticancer Ther. 2012 Aug;12(8):1021-32. doi: 10.1586/era.12.85. Review.

PMID:
23030222
15.

MicroRNA regulation of Cbx7 mediates a switch of Polycomb orthologs during ESC differentiation.

O'Loghlen A, Muñoz-Cabello AM, Gaspar-Maia A, Wu HA, Banito A, Kunowska N, Racek T, Pemberton HN, Beolchi P, Lavial F, Masui O, Vermeulen M, Carroll T, Graumann J, Heard E, Dillon N, Azuara V, Snijders AP, Peters G, Bernstein E, Gil J.

Cell Stem Cell. 2012 Jan 6;10(1):33-46. doi: 10.1016/j.stem.2011.12.004.

16.

Modified cell cycle status in a mouse model of altered neuronal vulnerability (slow Wallerian degeneration; Wlds).

Wishart TM, Pemberton HN, James SR, McCabe CJ, Gillingwater TH.

Genome Biol. 2008;9(6):R101. doi: 10.1186/gb-2008-9-6-r101. Epub 2008 Jun 20.

17.

Separase, securin and Rad21 in neural cell growth.

Pemberton HN, Franklyn JA, Boelaert K, Chan SY, Kim DS, Kim C, Cheng SY, Kilby MD, McCabe CJ.

J Cell Physiol. 2007 Oct;213(1):45-53.

PMID:
17450531
18.

Securin induces genetic instability in colorectal cancer by inhibiting double-stranded DNA repair activity.

Kim DS, Franklyn JA, Smith VE, Stratford AL, Pemberton HN, Warfield A, Watkinson JC, Ishmail T, Wakelam MJ, McCabe CJ.

Carcinogenesis. 2007 Mar;28(3):749-59. Epub 2006 Oct 27.

PMID:
17071631
19.

Monocarboxylate transporter 8 expression in the human placenta: the effects of severe intrauterine growth restriction.

Chan SY, Franklyn JA, Pemberton HN, Bulmer JN, Visser TJ, McCabe CJ, Kilby MD.

J Endocrinol. 2006 Jun;189(3):465-71.

20.

Thyroid hormones and fetal brain development.

Pemberton HN, Franklyn JA, Kilby MD.

Minerva Ginecol. 2005 Aug;57(4):367-78. Review.

PMID:
16170282

Supplemental Content

Loading ...
Support Center